InflaRx Q3 2026 Earnings Date & Estimates

InflaRx (NASDAQ:IFRX) (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company’s lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a. In 2023, vilobelimab received emergency use authorization from the U.S. Food and Drug Administration under the name Gohibic for certain critically ill adults hospitalized with COVID-19, including patients requiring mechanical ventilation or extracorporeal membrane oxygenation. InflaRx has also evaluated vilobelimab in other serious inflammatory conditions, including hidradenitis suppurativa, pyoderma gangrenosum and ANCA-associated vasculitis.

InflaRx conducts research and clinical development internationally, with operations and scientific activities rooted in Germany and clinical programs involving patients and research partners in multiple countries. The company is led by Niels Riedemann, M.D., who co-founded InflaRx and serves as its chief executive officer. Its pipeline remains focused on complement-targeted medicines for conditions in which excessive inflammation contributes to tissue damage and disease progression.